Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRS Followed by Erlotinib in EGFR-Mutant NSCLC
NCT01573702Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Dec 2012
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Dec 2012; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01573702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01573702.